| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. | Lancet | 2014 | 8.63 |
| 2 | Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. | Lancet Oncol | 2015 | 2.80 |
| 3 | A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma. | Eur J Cancer | 2014 | 0.84 |
| 4 | Expanded access programmes: patient interests versus clinical trial integrity. | Lancet Oncol | 2014 | 0.77 |